Key Points
- Merus VP Harry Shuman sold 8,300 shares on Nov. 25 at an average price of $95.92 for proceeds of $796,136, cutting his position by 43% to 11,002 shares (worth about $1.055M).
- Merus stock is trading near its 12‑month high (around $96) with a market cap of $7.29 billion and 50‑/200‑day SMAs of $92.41 and $70.73, respectively.
- Institutional investors own roughly 96.14% of the company, and analysts have a consensus rating of Hold with an average price target of $93.56.
Merus N.V. (NASDAQ:MRUS - Get Free Report) VP Harry Shuman sold 8,300 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $95.92, for a total value of $796,136.00. Following the completion of the transaction, the vice president directly owned 11,002 shares in the company, valued at approximately $1,055,311.84. The trade was a 43.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Merus Price Performance
Merus stock opened at $96.08 on Friday. The business has a 50 day simple moving average of $92.41 and a 200-day simple moving average of $70.73. Merus N.V. has a 12 month low of $33.19 and a 12 month high of $96.28. The stock has a market capitalization of $7.29 billion, a PE ratio of -18.13 and a beta of 1.26.
Hedge Funds Weigh In On Merus
A number of institutional investors have recently modified their holdings of MRUS. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company's stock worth $141,000 after purchasing an additional 362 shares during the period. Allianz Asset Management GmbH boosted its stake in Merus by 66.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 26,000 shares of the biotechnology company's stock worth $1,368,000 after buying an additional 10,400 shares during the last quarter. Voya Investment Management LLC grew its holdings in Merus by 26.3% in the 1st quarter. Voya Investment Management LLC now owns 78,280 shares of the biotechnology company's stock valued at $3,295,000 after buying an additional 16,280 shares during the period. Atle Fund Management AB lifted its holdings in shares of Merus by 69.7% during the 2nd quarter. Atle Fund Management AB now owns 59,889 shares of the biotechnology company's stock worth $3,150,000 after acquiring an additional 24,597 shares during the period. Finally, US Bancorp DE grew its holdings in Merus by 324.1% in the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company's stock valued at $124,000 after purchasing an additional 2,243 shares during the period. Institutional investors and hedge funds own 96.14% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have recently commented on MRUS shares. BMO Capital Markets restated a "market perform" rating and issued a $97.00 target price on shares of Merus in a research note on Friday, October 31st. Citigroup cut shares of Merus from a "buy" rating to a "neutral" rating and cut their price target for the stock from $101.00 to $97.00 in a report on Monday, September 29th. Truist Financial downgraded shares of Merus from a "buy" rating to a "hold" rating and raised their price objective for the company from $88.00 to $97.00 in a research report on Monday, September 29th. Leerink Partnrs cut Merus from a "strong-buy" rating to a "hold" rating in a research report on Sunday, October 5th. Finally, HC Wainwright cut Merus from a "buy" rating to a "neutral" rating and reduced their price target for the company from $135.00 to $97.00 in a report on Monday, September 29th. Three equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $93.56.
View Our Latest Analysis on Merus
Merus Company Profile
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
